Loading data for CLDX — first visit, this takes a few seconds.

アラート

Celldex Therapeutics Inc. (CLDX)

NasdaqCM: CLDX · リアルタイム株価 · USD

42.23

+0.44 (1.05%)

終値時点： Aug 18, 2026, 3:59 PM

1.05% (1D)

買気配	36.43
時価総額	3.28B
売上高（TTM）	158K
純利益（TTM）	-300.55M
ベータ	0.84
EPS（TTM）	-4.35
PER（TTM）	n/a
予想PER	-10.04
PBR（TTM）	4.59
PSR（TTM）	20770.57
Earnings Date	Nov 9, 2026

売気配	48.47
出来高	249,041
平均出来高（20日）	1,032,000
始値	42.51
前日終値	41.79
当日レンジ	41.73 - 43.20
52週レンジ	20.37 - 45.14
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

CLDXについて

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that spe...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 May 15, 1986

従業員数 198

上場取引所 NasdaqCM

ティッカー CLDX

ウェブサイト https://www.celldex.com

企業情報の全文

業績

2025年のCelldex Therapeuticsの売上高は1.54Mで、前年の7.02Mから-77.99%の減少でした。利益は-258.76Mで、63.91%の増加でした。

財務諸表

決算サプライズ

Celldex TherapeuticsはAug 6, 2026に四半期決算を発表しました：

売上高は $22K で、予想を下回りました $0, うち -96.99% の前年比減少.

EPSは -0.94 で、予想を上回りました 0.12, うち -10.59% の前年比減少.

次回決算発表

Celldex Therapeutics Inc.の決算発表予定日は Nov 9, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Simply Wall St.

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for inve...

1週間前 · Simply Wall St.

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operat...

1週間前 · Simply Wall St.

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return

Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is a...

1週間前 · Simply Wall St.

What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?

Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studi...

1週間前 · Zacks

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2ページ中1ページ

Celldex Therapeutics Inc. (CLDX)